InMed Pharmaceuticals (INM) Financial Report Summaries

Company Profile

Search within these filings

View filings

Exhibits within filings

Filing insights

Export filings list

Export a CSV file of filings or unique filing companies (up to first 5,000 results).

Download list of filings Download list of companies

External links

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigious
Readability	H.S. junior Avg

New words: advertising, AGM, anniversary, area, beneficially, biomarker, Cap, cellular, Chair, committee, contributor, cytokine, daily, deferred, deregulated, directorship, drawdown, equivalent, exceeded, fee, framework, GFAP, guide, inactive, independent, INF, inflammation, injury, installment, intravitreal, IVT, January, manner, margin, member, met, neurodegeneration, neurofilament, neuroinflammatory, NfL, nominee, pause, perception, pivotal, plasma, PN, policy, precisely, precluded, presidential, progression, protein, put, range, recommendation, recommended, replace, resale, resignation, SEPA, stable, standard, Standby, stockholder, suitable, tariff, tissue, TNF, toxicology, Voting, waived, wholly, wide, withheld, YA

Removed: absolute, accounted, delisting, imputed, institutional, intention, investigate, Notwithstanding, ready, representing

From filing 10-Q 2025 Q2

Financial report summary

Competition

CNBX Pharmaceuticals

Management Discussion

The Company has two operating and reportable segments based on the management approach which designates the internal reporting used by the Chief Operating Decision Maker (“CODM”), which is the Company’s Chief Executive Officer and the senior management team, for making decisions and assessing performance as the source of the Company’s reportable segments. The CODM allocates resources and assesses the performance of each operating segment based on potential licensing opportunities, historical and potential future product sales, operating expenses, and operating income (loss) before interest and taxes. The Company has determined its reportable segments to be InMed Pharmaceuticals (“InMed Pharma”) and BayMedica Commercial based on the information used by the CODM.